CTLA4 and neoplasm: Consequently, inhibitory antibodies were developed, such as ipilimumab, blocking CTLA-4 function and thereby facilitating positive co-stimulation with CD28 and allowing the rescue of exhausted CD8 T cells and NK cells, leading to tumor control of colon and melanoma tumors [26].